{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:06:14Z","timestamp":1764115574880,"version":"3.46.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["MH CZ \u2013 DRO-FNOs\/2023","MH CZ \u2013 DRO-FNOs\/2023","MH CZ \u2013 DRO-FNOs\/2023","MH CZ \u2013 DRO-FNOs\/2023"],"award-info":[{"award-number":["MH CZ \u2013 DRO-FNOs\/2023","MH CZ \u2013 DRO-FNOs\/2023","MH CZ \u2013 DRO-FNOs\/2023","MH CZ \u2013 DRO-FNOs\/2023"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s43440-025-00776-9","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T05:42:19Z","timestamp":1756446139000},"page":"1751-1759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Determination of serum concentrations of canrenone (active metabolite of spironolactone) in patients with heart failure with reduced ejection fraction: a cross-sectional study"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1802-0574","authenticated-orcid":false,"given":"Marie","family":"Lazarova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3981-8841","authenticated-orcid":false,"given":"Romana","family":"Urinovska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6618-754X","authenticated-orcid":false,"given":"Ivana","family":"Kacirova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3537-0342","authenticated-orcid":false,"given":"Jozef","family":"Dodulik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2410-0455","authenticated-orcid":false,"given":"Milan","family":"Grundmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7847-0967","authenticated-orcid":false,"given":"Jan","family":"Vaclavik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"issue":"6","key":"776_CR1","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s11936-009-0045-1","volume":"11","author":"EM Volz","year":"2009","unstructured":"Volz EM, Felker GM. How to use diuretics in heart failure. Curr Treat Options Cardiovasc Med. 2009;11(6):426\u201332. https:\/\/doi.org\/10.1007\/s11936-009-0045-1.","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"Suppl 1","key":"776_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1600-0773.1984.tb03626.x","volume":"54","author":"B Beermann","year":"1984","unstructured":"Beermann B. Aspects on pharmacokinetics of some diuretics. Acta Pharmacol Toxicol (Copenh). 1984;54(Suppl 1):17\u201329. https:\/\/doi.org\/10.1111\/j.1600-0773.1984.tb03626.x.","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"issue":"3","key":"776_CR3","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S0022-3565(25)29552-0","volume":"185","author":"W Sad\u00e9e","year":"1973","unstructured":"Sad\u00e9e W, Dagcioglu M, Schr\u00f6der R. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J Pharmacol Exp Ther. 1973;185(3):686\u201395.","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"776_CR4","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/jps.2600660841","volume":"66","author":"DL Phelps","year":"1977","unstructured":"Phelps DL, Karim A. Spironolactone: relationship between concentrations of dethioacetylated metabolite in human serum and milk. J Pharm Sci. 1977;66(8):1203. https:\/\/doi.org\/10.1002\/jps.2600660841.","journal-title":"J Pharm Sci"},{"issue":"10","key":"776_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709\u201317. https:\/\/doi.org\/10.1056\/NEJM199909023411001.","journal-title":"N Engl J Med"},{"issue":"9","key":"776_CR6","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","volume":"2","author":"J Butler","year":"2017","unstructured":"Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA, et al. Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial. JAMA Cardiol. 2017;2(9):950\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2017.2198.","journal-title":"JAMA Cardiol"},{"issue":"8","key":"776_CR7","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/ejhf.1802","volume":"22","author":"S de Denus","year":"2020","unstructured":"de Denus S, Leclair G, Dub\u00e9 MP, St-Jean I, Zada YF, Oussa\u00efd E, et al. Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial. Eur J Heart Fail. 2020;22(8):1451\u201361. https:\/\/doi.org\/10.1002\/ejhf.1802.","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"776_CR8","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. TOPCAT investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1313731.","journal-title":"N Engl J Med"},{"issue":"17","key":"776_CR9","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1056\/NEJMc1612601","volume":"376","author":"S de Denus","year":"2017","unstructured":"de Denus S, O\u2019Meara E, Desai AS, Claggett B, Lewis EF, Leclair G, et al. Spironolactone metabolites in TOPCAT-New insights into regional variation. N Engl J Med. 2017;376(17):1690\u20132. https:\/\/doi.org\/10.1056\/NEJMc1612601.","journal-title":"N Engl J Med"},{"issue":"2","key":"776_CR10","doi-asserted-by":"publisher","first-page":"e00131","DOI":"10.1002\/prp2.131","volume":"3","author":"RJ Keizer","year":"2015","unstructured":"Keizer RJ, Jansen RS, Rosing H, Thijssen B, Beijnen JH, Schellens JH, et al. Incorporation of concentration data below the limit of quantification in population Pharmacokinetic analyses. Pharmacol Res Perspect. 2015;3(2):e00131. https:\/\/doi.org\/10.1002\/prp2.131.","journal-title":"Pharmacol Res Perspect"},{"issue":"10458","key":"776_CR11","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","volume":"404","author":"PS Jhund","year":"2024","unstructured":"Jhund PS, Talebi A, Henderson AD, Claggett BL, Vaduganathan M, Desai AS, et al. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet. 2024;404(10458):1119\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(24)01733-1.","journal-title":"Lancet"},{"issue":"8","key":"776_CR12","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1093\/ndt\/gfad011","volume":"38","author":"NC Edwards","year":"2023","unstructured":"Edwards NC, Price AM, Steeds RP, Ferro CJ, Townend JN. Management of heart failure in patients with kidney disease-updates from the 2021 ESC guidelines. Nephrol Dial Transpl. 2023;38(8):1798\u2013806. https:\/\/doi.org\/10.1093\/ndt\/gfad011.","journal-title":"Nephrol Dial Transpl"},{"issue":"11","key":"776_CR13","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/cvr\/cvad083","volume":"119","author":"C Zoccali","year":"2023","unstructured":"Zoccali C, Mallamaci F, Adamczak M, de Oliveira RB, Massy ZA, Sarafidis P, et al. Cardiovascular complications in chronic kidney disease: a review from the European renal and cardiovascular medicine working group of the European renal association. Cardiovasc Res. 2023;119(11):2017\u201332. https:\/\/doi.org\/10.1093\/cvr\/cvad083.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"776_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/phar.4618","volume":"45","author":"S Mitsuboshi","year":"2025","unstructured":"Mitsuboshi S, Morizumi M, Imai S, Hori S, Kotake K. Association between mineralocorticoid receptor antagonists and kidney harm: A systematic review and meta-analysis of randomized controlled trials. Pharmacotherapy. 2025;45(1):43\u201353. https:\/\/doi.org\/10.1002\/phar.4618.","journal-title":"Pharmacotherapy"},{"issue":"11","key":"776_CR15","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1002\/ejhf.1987","volume":"22","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP, Mogensen UM, Jhund PS, Desai AS, Rouleau JL, Zile MR, et al. Serum potassium in the PARADIGM-HF trial. Eur J Heart Fail. 2020;22(11):2056\u201364. https:\/\/doi.org\/10.1002\/ejhf.1987.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"776_CR16","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/ejhf.2134","volume":"23","author":"JP Ferreira","year":"2021","unstructured":"Ferreira JP, Claggett BL, Liu J, Desai AS, Pfeffer MA, Anand IS, et al. Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. Eur J Heart Fail. 2021;23(5):776\u201384. https:\/\/doi.org\/10.1002\/ejhf.2134.","journal-title":"Eur J Heart Fail"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00776-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00776-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00776-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:01:21Z","timestamp":1764115281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00776-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["776"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00776-9","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"type":"print","value":"1734-1140"},{"type":"electronic","value":"2299-5684"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Marie Lazarova \u2013 was supported by the grant MH CZ \u2013 DRO-FNOs\/2023 in the work on this study; Ivana Kacirova \u2013 was supported by the grant MH CZ \u2013 DRO-FNOs\/2023 in the work on this study; Romana Urinovska \u2013 was supported by the grant MH CZ \u2013 DRO-FNOs\/2023 in the work on this study; Jozef Dodulik \u2013 was supported by the grant MH CZ \u2013 DRO-FNOs\/2023 in the work on this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosures"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}